Related references
Note: Only part of the references are listed.Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial
Lars Erik Kristensen et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
Andrew Ostor et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis
Gian Luca Erre et al.
RHEUMATOLOGY (2022)
Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases
Junko Takeshita et al.
JOURNAL OF RHEUMATOLOGY (2022)
A clinical and radiographic comparison of patients with psoriatic arthritis from different ethnic backgrounds
Tariq Aslam et al.
RHEUMATOLOGY (2021)
Effect of Multidomain Disease Presentations on Patients With Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie et al.
JOURNAL OF RHEUMATOLOGY (2021)
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
The epidemiology of psoriatic arthritis: A literature review
Paras Karmacharya et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2021)
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
SYSTEMATIC REVIEWS (2021)
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2019)
Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials A Systematic Review
Adrienne Strait et al.
JAMA NETWORK OPEN (2019)
Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
Alvin F. Wells et al.
RHEUMATOLOGY (2018)
The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus
Titilola Falasinnu et al.
CURRENT RHEUMATOLOGY REPORTS (2018)
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Peter Nash et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
P. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna Gladman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis Results Through Week Twenty-Four of the GO-VIBRANT Study
Arthur Kavanaugh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
A Review of Barriers to Minorities' Participation in Cancer Clinical Trials: Implications for Future Cancer Research
Ali Salman et al.
JOURNAL OF IMMIGRANT AND MINORITY HEALTH (2016)
Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis
Axel Patrice Villani et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Psoriasis and psoriatic arthritis in African-American patients-the need to measure disease burden
Gail S. Kerr et al.
CLINICAL RHEUMATOLOGY (2015)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Twenty Years Post- NIH Revitalization Act: Enhancing Minority Participation in Clinical Trials ( EMPaCT): Laying the Groundwork for Improving Minority Clinical Trial Accrual
Moon S. Chen et al.
CANCER (2014)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Challenging Assumptions About Minority Participation in US Clinical Research
Jill A. Fisher et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2011)
Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis
Vinod Chandran et al.
JOURNAL OF AUTOIMMUNITY (2010)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Rheumatic diseases in China
Qing Yu Zeng et al.
ARTHRITIS RESEARCH & THERAPY (2008)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Epidemiology of psoriatic arthritis in the population of the United States
JM Gelfand et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
Share Paper
